Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > $TLTFF Feb1 till now Declining Volume Rising stock price.

<< Previous

Bullboard Posts

Next >>

Comment by floatinketuckyon Mar 02, 2021 8:49pm

227 Views

Post# 32701807

RE:RE:$TLTFF Feb1 till now Declining Volume Rising stock price.

99942Apophis wrote: floatinketucky wrote
Bullish for sure.

Consider the Five year price range and what was not a factor in that price.

We never really knew if the FDA would grant a Phase 2 study. They did

We never really know if the FDA would grant a FTD. They did.

We never really knew if The FDA would consider BTD with 25 patients. They are.

And the price of the stock is not reflecting any of this.

Money is seeing this and the value at hand.

Is it too early to add to your list floatinketucky Shawn's remarks from the last NR of Feb. 24/2021

Shawn Shirazi, PhD, Chief Executive Officer, Theralase®, stated, "Each CSS Theralase launches for Study II will aid in our objective of enrolling and treating 10 patients in early 2021 to achieve a total of 25 patients for potential Breakthrough Designation Approval and approximately 75 to 100 additional patients in 2021 / 2022."